Verona Pharma

$7.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-3.32%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Verona Pharma and other stocks, options, and ETFs commission-free!

About VRNA

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom. The listed name for VRNA is Verona Pharma plc American Depositary Share.

CEO

David S. Zaccardelli

Employees

Headquarters

London, Greater London

Founded

2005

Market Cap

389.75M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

36.22K

High Today

$7.80

Low Today

$7.46

Open Price

$7.65

Volume

45.15K

52 Week High

$15.71

52 Week Low

$2.01

Collections

VRNA Earnings

-$1.09

-$0.73

-$0.36

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, Pre-Market